Drug Topics

JANUARY 3, 2023

Keep your pharmacy services up to date with the latest 2023 ACIP vaccination schedule updates and recommendations.

Vaccines 502

Vaccines 502

PharmaVoice

JANUARY 3, 2023

Durect’s chief medical officer altered his retirement plans to take a leading role at the company, which is developing a treatment for severe alcohol-associated hepatitis.

279

279

Drug Topics

JANUARY 3, 2023

A look at what’s to come in the January issue of Drug Topics®.

247

247

PharmaVoice

JANUARY 3, 2023

A preview of the top trends on the minds of industry and market leaders for the new year.

239

239

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

JANUARY 3, 2023

Researcher modeling the cost effectiveness of chimeric antigen receptor T-cell therapy (CAR-T) therapy and antibody conjugate found that they fell short.

247

247

Pharmacy Times

JANUARY 3, 2023

In addition to the physical symptoms of long COVID, patients have reported vocal, verbal, and cognitive issues that disrupt their ability to communicate.

Communication 171

Communication 171

Pharmacy Times

JANUARY 3, 2023

Study finds a strong decline in hepatitis C incidence in the years immediately following broad access to direct-acting antiviral drugs.

149

149

STAT

JANUARY 3, 2023

A diverse and inclusive workforce benefits science and research. But unless it includes people living with a disability — the largest minority group in the U.S. and around the world — research will never be fully representative and science will not reach its full potential. Although 27% of U.S. adults live with a disability, only 10% of science, engineering, and health doctorate holders, and less than 2% of researchers funded by the National Institutes of Health, report having a di

141

141

Pharmacy Times

JANUARY 3, 2023

Indication can play a major role in pharmacists recommending brain health products.

132

132

Fierce Pharma

JANUARY 3, 2023

COVID-19 tracker: AstraZeneca workers who were fired for refusing vaccine file lawsuit. kdunleavy. Tue, 01/03/2023 - 10:31.

Vaccines 125

Vaccines 125

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmacy Times

JANUARY 3, 2023

Pharmacists play a vital role in counseling and educating families about medication safety for these products.

128

128

Fierce Healthcare

JANUARY 3, 2023

Physician group practices struggle with bundled payments: study. fdiamond. Tue, 01/03/2023 - 14:29.

115

115

Pharmacy Times

JANUARY 3, 2023

The subcutaneous formulation could enhance treatment options by providing high consistency in drug exposure and a convenient administration method.

FDA 123

FDA 123

Fierce Healthcare

JANUARY 3, 2023

Oregon health agency approves Amazon, One Medical acquisition, moving $3.9B deal one step forward. hlandi. Tue, 01/03/2023 - 21:44.

112

112

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Drug Store News

JANUARY 3, 2023

Gail Lebovic’s recent move in health care came in 2020, with the formation of Silicon Valley Innovations, and its OTC flagship product, NasoClenz.

111

111

Fierce Healthcare

JANUARY 3, 2023

Scripps Health reaches $3.5M proposed settlement to compensate victims of 2021 ransomware attack. aburky. Tue, 01/03/2023 - 13:13.

111

111

pharmaphorum

JANUARY 3, 2023

Encouraged by new data, Newron Pharmaceuticals has said it will start a registration study of would-be blockbuster evenamide in treatment-resistant schizophrenia (TRS) later this year. The Italian biopharma said it had decided to press ahead with the new study after assessing results from 100 patients with TRS in open-label studies who received the glutamate modulator drug as an add-on to their current therapy for more than six months.

Labelling 106

Labelling 106

Drug Store News

JANUARY 3, 2023

International Delight’s Friends Manhattan Hazelnut Mocha creamer contains hints of hazelnut and mocha.

106

106

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

pharmaphorum

JANUARY 3, 2023

The way pharmaceutical companies manage data carries inherent risks, as exemplified by the constant scandals about data breaches. Is there anything that can be done about this? A potential solution could be provided by decentralised storage, which could not only improve data security, but also open opportunities for business process automation, improved data governance, and potentially new revenue streams.

Medical Records 105

Medical Records Pharmaceutical Companies Pharmaceutical Companies 105

STAT

JANUARY 3, 2023

The number of people in the United States hospitalized with Covid-19 is about to surpass the figure reached during this summer’s spike, federal data show , as a confluence of factors — from the continued evolution of the coronavirus to holiday gatherings — drives transmission. Notably, the number of people hospitalized with Covid — roughly 40,000 — is still far below the winter waves of 2020-2021 and 2021-2022 (the wave driven by the original Omicron variant) a

Hospitals 102

Hospitals 102

The Checkup by Singlecare

JANUARY 3, 2023

After engaging in a fun holiday season with indulgent food and festive drinks, it’s not unusual to long for a reset. For some this takes the form of “Dry January,” a month without drinking any alcohol—or significantly reduced alcohol consumption. “Starting a new year is a good time to make commitments for healthier behaviors,” says Anna Legreid Dopp, Pharm.D. , a senior director at American Society of Health-System Pharmacists (ASHP).

98

98

STAT

JANUARY 3, 2023

If rebates had been required for price hikes on most of the nearly 100 medicines covered by Medicare during a recent three-year period, the U.S. government program would have saved $3.7 billion, or 3% of the total spending on so-called Part B medicines, a new analysis found. More specifically, 70 of the 93 top-selling drugs covered by the Medicare Part B program – which are typically pricier medicines that are administered by physicians or in hospitals – between 2018 and 2020 would

Immunization 98

Immunization Hospitals 98

Drug Store News

JANUARY 3, 2023

Albertsons has been granted a Jan. 17 review of the temporary restraining order against its previously announced $6.85-per-common-share special dividend.

98

98

STAT

JANUARY 3, 2023

Over the past three years, many Americans learned more about epidemiology than they ever knew before. From Covid-19 to mpox to polio, a new generation of citizen scientists is now joining trained professionals in analyzing public health data, forecasting trends, and making personal decisions based on the latest outbreak patterns. But professionals and everyday observers alike are running up against one of the most significant problems in the world of health care data science: the available infor

98

98

pharmaphorum

JANUARY 3, 2023

As December 2022 closed out, Pfizer announced positive top-line results from its phase 3 BENEGENE-2 study evaluating fidanacogene elaparvovec (SPK-9001), its investigational gene therapy for treatment of adult males with moderately severe to severe haemophilia B. Haemophilia is a rare genetic bleeding disorder that causes the blood to take a long time to clot because of a deficiency in one or several blood clotting factors.

FDA 98

FDA 98

STAT

JANUARY 3, 2023

As inflation-weary shoppers try to make ends meet, many are turning to a modern twist on the layaway plan: buy now, pay later. But while platforms like Afterpay and Affirm were originally built to take the sting out of online shopping, these new financing options are beginning to creep into the world of health care. “Buy now, pay later is a small fraction of the health space, but it is exploding,” said Jay Zagorksy, an economist at the Questrom School of Business at Boston Universi

98

98

Drug Store News

JANUARY 3, 2023

The United States Court of Appeals for the Federal Circuit has granted a motion to temporarily enjoin the generic launch by Teva and Apotex of Hetlioz.

98

98

STAT

JANUARY 3, 2023

A House investigation released last week unearthed a trove of documents that shed new light on the polarizing approval and disastrous rollout of Aduhelm, the first new drug for Alzheimer’s disease in two decades. But crucial questions remain for the Food and Drug Administration, Biogen, and the future of treating Alzheimer’s disease. The FDA has not made clear just what it has changed since the Aduhelm debacle, and the revelations about its inner workings — and the blow to i

FDA 98

FDA Documentation 98

Fierce Healthcare

JANUARY 3, 2023

'Podnosis': Digital redlining in healthcare and breaking down barriers to care for gender-diverse populations. tcarey. Tue, 01/03/2023 - 15:06.

98

98

STAT

JANUARY 3, 2023

Paying people to participate in medical research has been proposed as a way to narrow racial and ethnic gaps in who signs up for clinical trials and other research studies. But a new study finds that if the amount is too small, it could have the opposite effect. Offering $100 to participate in a Covid-19 study enticed affluent and white people while doing little to increase the participation of people from low-income or non-white households.

98

98

Drug Store News

JANUARY 3, 2023

The Flexforce scheduling service is now available across the retailer’s Illinois, Indiana and Missouri stores.

98

98

STAT

JANUARY 3, 2023

For almost three years, hospitals and health insurers have been riding the waves of the Covid-19 pandemic. Even though they can better predict what lies ahead in 2023, there remain several big unknowns. STAT’s business reporters will be paying attention to three trends in particular: the end of the public health emergency, how hospital price hikes will affect people’s paychecks, and Medicare Advantage’s explosive growth.

Insurance 98

Insurance Hospitals Health Insurance Companies 98

European Pharmaceutical Review

JANUARY 3, 2023

A marketing authorisation application (MAA) has been submitted by The Janssen Pharmaceutical Companies of Johnson & Johnson to the European Medicines Agency (EMA) for approval of talquetamab, a bispecific t-cell engager antibody for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). Talquetamab is an investigational, off-the-shelf treatment targeting both GPRC5D, a novel drug target that is on some normal cells but overexpressed on myeloma cells, and CD3 on t-cell

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies FDA 98